Colorectal Cancer Drugs Market Trends Size Analysis Report 2022
According to the DataM market research report, the global colorectal cancer drugs market size was valued at USD billion in 2021, it is projected to reach USD billion by 2029, with growth at a CAGR of % over the forecast period 2022-2029.
Colorectal cancer (CRC), or bowel cancer, is cancer affecting the large intestine and the rectum. They have also named colon tumors or rectal cancer, depending upon where they begin.
The increasing growth of the global colorectal cancer drugs market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
Market Drivers:
Globally, the number of colorectal cancers has been increasing. According to the American Cancer Society (ACS), there were around 101,420 new cases of colon cancer and around 44,180 new cases of rectal cancer registered in the USA in 2019. The diagnosed incident cases of colorectal cancer are expected to increase by 27.3% to 672,400 cases by 2037. This growth can be attributed to factors such as a low-fiber diet, obesity, and consumption of alcohol and tobacco, amongst others. The rise in the number of colorectal cases will add to the overall size of the global colorectal cancer drugs market.
Market Restraints:
The growing usage of biologics and targeted therapies restrains the colorectal cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs, which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV, where chemical drugs are ineffective. For instance, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab, and panitumumab. The advantages of biological drugs and targeted therapies over conventional chemical drugs might negatively influence the market.
Market Opportunities:
Targeted therapies have already begun to increase the lifespan of metastatic colorectal cancer patients compared with chemotherapy-only therapy. It includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is important because of its specificity toward cancer cells while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/colorectal-cancer-drugs-market
COVID-19 Impact Analysis:
Due to the coronavirus pandemic many pharmaceutical industries have suspended the clinical trials. In a study, it is estimated that approximately 12,000 clinical trials are going on in the area of cancer. If these trails are stopped or suspended for any reason, it will have a profound impact on the industry. Beyond this, loss of the potential health benefits for patients already enrolled in the trials, the cost of an oncology phase 3 clinical trial is on average at least USD 20 million, which will impose a huge financial hurdle on companies for gaining approval for trial and identification for the patients for the second time.
According to, the Centre for Drug Development (UK), the pandemic initially drew recruitment for UK clinical trials to an almost complete pause. From about April 2020 until July or August 2020, all British hospitals stopped recruiting patients into new clinical trials, and they even stopped treating some patients already in clinical trials, if the visits weren't deemed completely necessary – so clinical development definitely had to pause in the year 2020. There was also a complete block on opening new trials as well.
Recent Developments in the Industry:
- In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company received the approval to acquire Celgene Corporation for $74 billion.
Market Segmentation:
As per the research analysis, the global colorectal cancer drugs market is segmented by type into vascular endothelial growth factor inhibitors, programmed cell death protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, tyrosine kinase (TKI) inhibitors, immunomodulators, and BRAF or MEK inhibitors. By therapy into immunotherapy, targeted therapy, and chemotherapy and by distribution channels the market is further segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.
- On the basis of type, the vascular endothelial growth factor inhibitors segment is estimated to grow at the highest CAGR of % during the forecast period (2022-2029). Vascular endothelial growth factor inhibitors are expected to have the largest share. The Vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) inhibitors are the agents that inhibit VEGF and VEGFR. VEGR and VEGFR (a tyrosine kinase receptor) signaling modulate angiogenesis, making new blood vessels from existing blood vessels. They are used to treat various types of cancers. The drugs included in this type Avastin, Eylea, cometriq. The Avastin segment, picked up $7.12 billion of global annual sales by 2019.
- Based on therapy, the immunotherapy segment accounted for the largest market share of around % in 2020 and is expected to grow at a CAGR of % during the forecast period (2022-2029). The immunotherapy segment led the colorectal cancer therapeutics market by therapy, with a share of nearly % in 2021. This class is expected to gain further traction throughout the forecast period. Immunotherapeutics tend to have some adverse effects when compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are likely to stifle the growth of chemotherapeutics and encourage the adoption of immunotherapeutics and other targeted treatments.
Make an inquiry before purchasing the full report @ https://www.datamintelligence.com/enquiry/colorectal-cancer-drugs-market
Geographical Classification:
The global colorectal cancer drugs market is segmented into major countries including North America, Europe, South America, Asia Pacific, the Middle East, and Africa.
North America Colorectal Cancer Drugs Market:
Geographically, North America is leading the market with a high prevalence of colorectal cancer. In 2020, North America earned USD billion, owing to the new product launches in and around the region. Thus, the factors mentioned above are likely to help this region dominate the future market too.
On the contrary, the continuously improving healthcare infrastructure, coupled with the rise in disposable incomes of people in the Asia Pacific, is expected to boost the regional market in the forecast period. Colorectal cancer is a major reason for the rise in mortality rates, coupled with the rising awareness about colorectal cancer therapeutics that will help this region attract high Colorectal Cancer Therapeutics Market revenue in the near future.
Competitive Analysis:
The colorectal cancer drugs market is competitive. However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of cases. Few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the blood cancer drugs market crowded with new products in the next couple of years.
Major Companies:
Major key companies which are contributing to the growth of the market include Genentech, Pfizer, Roche, Sanofi, Bristol-Myers Squibb, Amgen, Merck & Co, Teva Pharmaceuticals, and Eli Lilly and Company, and Abbott Laboratories.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regards to the scope offered will be addressed within 24- 48 hours.
3) An excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
- Visualize the composition of the global colorectal cancer drugs market segmentation by type, therapy, distribution channels, and country highlighting the key commercial assets and players.
- By Type Vascular endothelial growth factor inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, and BRAF or MEK Inhibitors
- By Therapy: Immunotherapy, Targeted Therapy, and Chemotherapy
- By Distribution channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Country: North America, South America, Europe, Asia Pacific and the Middle East and Africa
- Identify commercial opportunities in the global colorectal cancer drugs market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as porter's five forces analysis, supply chain analysis, pricing analysis, regulatory analysis, reimbursement analysis, and unmet needs, etc.
- Excel data sheet with thousands of data points of global blood cancer drugs market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
- The report will provide access to approximately 69 market data tables, 68 figures, and close to 200 pages.
Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email:Send Email
Phone: +1 877 441 4866
Country: United States
Website: https://www.datamintelligence.com/research-report/colorectal-cancer-drugs-market
